C4 Therapeutics (CCCC) EBITDA Margin Growth (1y) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) EBITDA Margin Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -1,651.00 |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 29,091.00 |
| 10 | C4 Therapeutics | 492.73 Mn | 239.06 Mn | - | 4,311.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4,311.00 |
| Mar 31, 2026 | -4,871.00 |
| Dec 31, 2025 | 51,829.00 |
| Sep 30, 2025 | -12,257.00 |
| Jun 30, 2025 | -26,239.00 |
| Mar 31, 2025 | 65,726.00 |
| Dec 31, 2024 | 41,932.00 |
| Sep 30, 2024 | 6,730.00 |
| Jun 30, 2024 | 123,162.00 |
| Mar 31, 2024 | -9,642.00 |
| Dec 31, 2023 | 19,402.00 |
| Sep 30, 2023 | 22,986.00 |
| Jun 30, 2023 | -121,226.00 |
| Mar 31, 2023 | -55,393.00 |
| Dec 31, 2022 | -126,575.00 |
| Sep 30, 2022 | -19,568.00 |
| Jun 30, 2022 | 2,816.00 |
| Mar 31, 2022 | -13,366.00 |
| Dec 31, 2021 | 15,282.00 |
| Sep 30, 2021 | -6,812.00 |